Humoral and cellular effects of the K(+)-channel activator cromakalim in man.
The effect of cromakalim, a K(+)-channel activator, on the plasma renin-angiotensin-aldosterone system, catecholamines and alpha-atrial natriuretic peptide, and on the intraerythrocyte concentration and transmembrane fluxes of Na+ and K+ has been investigated in 18 normal male subjects, in a double-blind parallel study. After a run-in period on placebo for 1 week, the subjects were treated either with placebo (n = 6) or cromakalim (n = 12) for 1 week. Plasma renin activity was significantly increased during cromakalim. No effect of cromakalim on plasma angiotensin II, aldosterone, adrenaline, noradrenaline and alpha-atrial natriuretic peptide was demonstrated. The intra-erythrocyte K+ concentration was decreased during cromakalim administration and Ca2(+)-dependent K(+)-channels in red blood cells were increased.
Lijnen
P
P
Department of Pathophysiology, University of Leuven, Belgium.
Fagard
R
R
Staessen
J
J
Weiping
T
T
Moerman
E
E
Amery
A
A
D000328:Adult; D000959:Antihypertensive Agents / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology*; D001693:Biological Transport, Active / Q000187:drug effects; D019806:Cromakalim; D004311:Double-Blind Method; D004912:Erythrocytes / Q000187:drug effects*; D006801:Humans; D008297:Male; D010276:Parasympatholytics / Q000494:pharmacology; D015221:Potassium Channels / Q000187:drug effects; D011758:Pyrroles / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D012084:Renin-Angiotensin System / Q000187:drug effects*; D016037:Single-Blind Method; D014665:Vasodilator Agents / Q000494:pharmacology
D000959:Antihypertensive Agents; D001578:Benzopyrans; D010276:Parasympatholytics; D015221:Potassium Channels; D011758:Pyrroles; D014665:Vasodilator Agents; D019806:Cromakalim